Skip to main content

Starting your child on CRYSVITA

XLH is a lifelong, progressive disease, which means it may continue to get worse over time. Talk to your child’s doctor about CRYSVITA and if it could be right for them.

Actor portrayal

Talk to your doctor about dosing for CRYSVITA

Your child’s doctor may discuss the following:

  • When starting CRYSVITA, the recommended dose is once every 2 weeks
  • The dosage (the amount of CRYSVITA your child takes) is based on your child's body weight and will be determined by the doctor. In some cases, this may require more than 1 injection
  • After initial treatment, your child’s doctor may have to adjust their dose

Discontinue oral phosphate and/or active vitamin D analogs (eg, calcitriol, paricalcitol, doxercalciferol, calcifediol) 1 week prior to initiation of treatment.

If you miss a dose, be sure to receive your next CRYSVITA dose as soon as possible. To avoid missed doses, CRYSVITA may be given up to 3 days before or after the scheduled treatment date.

Discontinue oral phosphate and/or active vitamin D analogs (eg, calcitriol, paricalcitol, doxercalciferol, calcifediol) 1 week prior to initiation of treatment.

If you miss a dose, be sure to receive your next CRYSVITA dose as soon as possible. To avoid missed doses, CRYSVITA may be given up to 3 days before or after the scheduled treatment date.

CRYSVITA is given as an injection under the skin by a healthcare provider

Your child will receive an injection in 1 of 4 places, to be rotated with each injection:

  • Upper arm
  • Upper thigh
  • Buttocks
  • Stomach
Injection sites on upper arm, stomach, upper leg, and buttocks

CRYSVITA works to treat XLH as long as your child continues to receive it as prescribed.

Have questions about access and reimbursement?

Connect with a Kyowa Kirin Cares case manager, who can help you understand your financial options.

get support

Appointments can feel short. Make sure the conversation with their doctor is a productive one

Use this doctor discussion guide to help you prepare for your child’s visit. That way, you can have a better conversation about starting them on CRYSVITA.

DOWNLOAD GUIDE

I’ve been on CRYSVITA for about 3 years now, and I feel it's working for me.

Leah, age 16,

Living with XLH

read leah’s story
Leah, real CRYSVITA patient

Stay informed

Learn more about CRYSVITA, connect with a support community, and receive invites to important educational events.

Sign Up
What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).


What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

Important Safety Information

You should not take CRYSVITA if:

  • You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Your phosphorus levels from a blood sample are within or above the normal range for age.
  • You have kidney problems.

What is the most important information you should know about CRYSVITA?

  • Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA. Your treatment may need to be discontinued for serious allergic reactions.
  • High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels. If you are already taking CRYSVITA, dose interruption and/or dose reduction may be required based on your serum phosphorus levels.
  • Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma). Call your doctor if you develop an injection site reaction. CRYSVITA may be discontinued if severe injection site reactions occur.

What are the possible side effects of CRYSVITA?

  • Adverse reactions that were seen in children with XLH are:

    • Fever
    • Injection site reaction
    • Cough
    • Vomiting
    • Pain in arms and legs
    • Headache
    • Tooth abscess
    • Dental cavities
    • Diarrhea
    • Decreased vitamin D levels
    • Toothache
    • Constipation
    • Muscle pain
    • Rash
    • Dizziness
    • Nausea
  • Adverse reactions that were seen in adults with XLH are:

    • Back pain
    • Headache
    • Tooth infection
    • Restless legs syndrome
    • Decreased vitamin D levels
    • Dizziness
    • Constipation
    • Muscle spasms
    • Phosphorus levels increased in the blood
  • Narrowing of the spaces within the spine is common in adults with XLH, and pressure on the spinal cord has been reported in adults taking CRYSVITA. It is not known if taking CRYSVITA worsens the narrowing of the spaces within the spine or the pressure on the spinal cord.

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

  • Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

  • An allergic reaction such as rash or hives
  • A rash, swelling, bruising, or other reaction at the injection site
  • New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

Important Safety Information

You should not take CRYSVITA if:

  • You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Your phosphorus levels from a blood sample are within or above the normal range for age.
  • You have kidney problems.

What is the most important information you should know about CRYSVITA?

  • Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA. Your treatment may need to be discontinued for serious allergic reactions.
  • High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels. If you are already taking CRYSVITA, dose interruption and/or dose reduction may be required based on your serum phosphorus levels.
  • Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma). Call your doctor if you develop an injection site reaction. CRYSVITA may be discontinued if severe injection site reactions occur.

What are the possible side effects of CRYSVITA?

  • Adverse reactions that were seen in children with XLH are:

    • Fever
    • Injection site reaction
    • Cough
    • Vomiting
    • Pain in arms and legs
    • Headache
    • Tooth abscess
    • Dental cavities
    • Diarrhea
    • Decreased vitamin D levels
    • Toothache
    • Constipation
    • Muscle pain
    • Rash
    • Dizziness
    • Nausea
  • Adverse reactions that were seen in adults with XLH are:

    • Back pain
    • Headache
    • Tooth infection
    • Restless legs syndrome
    • Decreased vitamin D levels
    • Dizziness
    • Constipation
    • Muscle spasms
    • Phosphorus levels increased in the blood
  • Narrowing of the spaces within the spine is common in adults with XLH, and pressure on the spinal cord has been reported in adults taking CRYSVITA. It is not known if taking CRYSVITA worsens the narrowing of the spaces within the spine or the pressure on the spinal cord.

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

  • Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
  • Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

  • An allergic reaction such as rash or hives
  • A rash, swelling, bruising, or other reaction at the injection site
  • New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information.